Factors influencing outcome and incidence of late complications in children who underwent allogeneic hematopoietic stem cell transplantation for hemoglobinopathy

Pediatric Hematology and Oncology

Volumn 29, Issue 8, 2012, Pages 694-703

  Khalil, Abdalla ^a   Zaidman, Irena ^a   Elhasid, Ronit ^b   Peretz Nahum, Monique ^a   Futerman, Boris ^c   Ben Arush, Myriam ^a,d  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b Dana Children's Hospital   (Israel)

^c Rambam Health Care Campus   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Hemoglobinopathy; Late complications; Sickle cell disease

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFERASIROX; DEFEROXAMINE; FERRITIN; HYDROXYUREA; LAMIVUDINE; METHOTREXATE; THIOTEPA; URSODEOXYCHOLIC ACID;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; APLASTIC ANEMIA; ARTICLE; AVASCULAR NECROSIS; BONE DISEASE; BRONCHIOLITIS OBLITERANS; CATARACT; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CORNEA PERFORATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; IRON CHELATION; IRON OVERLOAD; KERATOCONJUNCTIVITIS; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; SCHOOL CHILD; SECONDARY OSTEOPOROSIS; SEIZURE; SHORT STATURE; SICKLE CELL ANEMIA; SPLENECTOMY; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; ENDOCRINE SYSTEM DISEASES; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMANS; INCIDENCE; INFANT; MALE; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867952034     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.725198     Document Type: Article

References (36)

1. Di Bartolomeo P, Santarone S, Di Bartolomeo E, et al. Long-Term results of survival in patients with thalassemiamajor treated with bonemarrow transplantation. Am J Hematol. 2008;83:528-530.
2. Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. HematologyAmSoc Hematol Educ Prog. 2008;2008:125-133.
3. Lee JW, Kang HJ, Kim EK, et al. Effect of iron overload and iron-chelation therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2009;44:793-797.
4. OlivieriNF,NathanDG,MacMillan JH, et al. Survival inmedically treated patientswith homozygous B-Thalassemia.NewEngl J Med. 1994;331:574-578.
5. Shalet SM, Didi M, Oglivy-Stuart Al, et al. Growth and endocrine function after bonemarrow transplantation. Clin Endocrinol. 1995;42:333-339.
6. Lucarelli G, GalimberiM, Polchi P, et al. Bonemarrow transplantation in patients with thalassemia. N England JMed. 1990;322:417-421.
7. Michel G, Socie G, Gebhard F, et al. Late effects of allogeneic bonemarrow transplantation for children with acute myeloblastic leukemia in first complete remission: The impact of conditioning regimen without total body irradiation-A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 1997;15:2238-2246.
8. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood. 2004;104:1201-1203.
9. Gaziev J, Sodani P, Lucarelli G, et al. Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft. Bone Marrow Transplant. 2008;42:397-404.
10. Shalitin S, PhillipM, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006;37:1109-1117.
11. Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-Thalassemia major in North America. Blood. 2004;104:34-39.
12. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
13. Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: Added clarity from the consensusdiagnoses. Bone Marrow Transplant. 2009;43:149-153.
14. Kalhs P, Schwarzinger I, AndersonG, et al. A retrospective analysis of the long-Termeffect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronicmyelognous leukemia. Blood. 1995;86:2028-2032.
15. Mathews V, George B, Lakshmi KM, et al. Impact of pretransplant splenectomy on patients with B-Thalassemia major undergoing a matched-related allogeneic stem cell transplantation. Pediatr Transplant. 2009;13:171-176.
16. MichalletM, Corront B, Bosson JL, et al. Role of splenectomy in incidence and severity of acute graftversus-host disease: Amulticenter study of 157 patients. Bone Marrow Transplant. 1991;8:7-13.
17. Gaziev J, Sodani P, Polchi P, et al. Bone marrow transplantation in adults with thalassemia. Treatment and long termfollow up. Ann N Y Acad Sci. 2005;1054:196-205.
18. Raiola G, Galati MC, De Sanctis V, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab. 2003;16SUPPL2):259-266.
19. Gaziev J, Galimberti M, Giardini C, et al. Growth in children after bone marrow transplantation for thalassemia. Bone Marrow Transplant. 1993;12:100-101.
20. Li CK, Chik KW,Wong GW, et al. Growth and endocrine function following bonemarrow transplantation for thalassemiamajor. Pediatr Hematol Oncol. 2004;5:411-419.
21. Bakker B, Oostdijk W, Bresters D, et al. Disturbances of growth and endocrine function after busulphan-based conditioning for hematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 2004;33:1049-1056.
22. Ghany AM, Tutschka PJ, McGhee RB Jr, et al. Cyclosporine-Associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy. Transplantation. 1991;52:310-315.
23. Patchell RA. Neurological complications of organ transplantation. Ann Neurol. 1994;36:688-703.
24. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993;119:1175-1180.
25. Mieler WF, Kivlin JD. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999;106:1564-1570.
26. Tichelli A,Duell T,Weiss M, et al. Late-onset keratoconjunctivitis sicca syndrome after bonemarrow transplantation: Incidence and risk factors. European group or blood and marrow transplantation (EBMT) working party on late effects. Bone Marrow Transplant. 1996:17:1105-1111.
27. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassemia. Br J Hematol. 2004;127:127-139.
28. Stern JM, Sullivan KM, Ott SM, et al. Bone density loss after allogeneic hematopoietic stem cell transplantation: A prospective study. Biol Blood Marrow Transplant. 2001;7:257-264.
29. Socie G, Selimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bonemarrow transplantation: Clinical findings, incidence and risk factors. Br J Hematol. 1994;86:624-628.
30. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 28;425-425.
31. Leung W, Ahn H, Rose SR, et al. Aprospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore). 2007;86:215-224.
32. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
33. Taskinen M, Lipsanen-Nyman M, Tiitinen A, et al. Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J Pediatr Hematol Oncol. 2007;8:29529-29534.
34. Modell B, Khan M, Darlison M. Survival in beta-Thalassemiamajor in the UK: Data fromthe UK thalassemia register. Lancet. 2000;355:2051-2052.
35. Bashey A, Owen I, Bashey A, et al. Late onset immune pancytopenia following bone marrow transplantation. Brit J Hematol. 1991;78:268-274.
36. Hartert A, Willenbacher W, Gunzelmann S, et al. Successful treatment of thrombocytopenia and hemolytic anemia with IvIG in a patient with lupus-like syndrome after mismatched related PBSCT. Bone Marrow Transplant. 2001;27:337-340.